August 2022
-
08.12.2022 Vaccines Vaccines Pfizer Announces Positive Top-Line Results from Phase 3 Study of 20-Valent Pneumococcal Conjugate Vaccine in Infants
June 2022
-
06.29.2022 Vaccines Covid-19 Vaccines Pfizer and BioNTech Announce New Agreement with U.S. Government to Provide Additional Doses of COVID-19 Vaccine -
06.25.2022 Vaccines Vaccines Pfizer and BioNTech Announce Omicron-Adapted COVID-19 Vaccine Candidates Demonstrate High Immune Response Against Omicron -
06.23.2022 Financial Investments Vaccines Valneva and Pfizer Announce Closing of Equity Investment -
06.20.2022 Vaccines Vaccines Valneva and Pfizer Enter into an Equity Subscription Agreement and Update Terms of Collaboration Agreement for Lyme Disease Vaccine Candidate VLA15 -
06.17.2022 Vaccines Covid-19 Vaccines Pfizer-BioNTech COVID-19 Vaccine Receives FDA Emergency Use Authorization for Children 6 Months through 4 Years of Age -
06.06.2022 Financial Covid-19 Investments Vaccines Pfizer to Invest $120 Million to Produce COVID-19 Oral Treatment in the U.S.
May 2022
-
05.23.2022 Vaccines Covid-19 Vaccines Pfizer-BioNTech COVID-19 Vaccine Demonstrates Strong Immune Response, High Efficacy and Favorable Safety in Children 6 Months to Under 5 Years of Age Following Third Dose -
05.17.2022 Vaccines Covid-19 Vaccines Pfizer and BioNTech Granted U.S. Emergency Use Authorization for Booster Dose of Their COVID-19 Vaccine in Children 5 Through 11 Years of Age -
05.13.2022 Vaccines Covid-19 Vaccines Pfizer and BioNTech Provide Update on COVID-19 Vaccine Supply Agreement with European Commission
April 2022
-
04.14.2022 Covid-19 Vaccines Pfizer and BioNTech Announce Data Demonstrating High Immune Response Following a Booster Dose of their COVID-19 Vaccine in Children 5 Through 11 Years of Age